Novavax misses quarterly estimates, but vaccine maker narrows losses as it slashes costs

Vaccine maker Novavax on Wednesday reported fourth-quarter revenue and earnings that missed Wall Street's estimates and reiterated plans to cut costs as it fights to stay afloat. Still, Novavax narrowed its losses in the quarter from the same period a year ago, even as demand for the biotech company's Covid vaccine – its only marketable product – and other products that combat the virus continue to plummet worldwide. Here's what Novavax reported for the fourth quarter compared with what Wall Street was expe ...